SCHEMBL398656

SCHEMBL398656

Cc1cccc(C(=O)Nc2cccc(Oc3ccc4c(c3)NC(=O)C4=Cc3cc(C(=O)NCCCN4CCCC4)c[nH]3)c2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT2 P31751 4/20 0.53
PDPK1 O15530 2/20 0.53
NTRK1 P04629 2/20 0.46
NTRK2 Q16620 2/20 0.46
MET P08581 1/20 0.45
PDGFRB P09619 1/20 0.45
KDR P35968 1/20 0.45
FLT3 P36888 1/20 0.45
AURKB Q96GD4 1/20 0.45
KMT2A Q03164 3/20 0.45
RAD52 P43351 1/20 0.45
GSK3A P49840 1/20 0.45
GSK3B P49841 1/20 0.45
CDK5 Q00535 1/20 0.45
CDK5R1 Q15078 1/20 0.45
NTRK3 Q16288 1/20 0.44
PIM1 P11309 3/20 0.44
SMYD2 Q9NRG4 1/20 0.44
MITF O75030 2/20 0.43
MCHR1 Q99705 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10091934 1.00 AKT2 (0.53) AKT2PDPK1NTRK1NTRK2MET
SCHEMBL14073768 0.90 NTRK2 (0.53) AKT2PDPK1NTRK1NTRK2NTRK3
SCHEMBL396734 0.90 AKT2 (0.60) AKT2PDPK1NTRK1NTRK2MET
SCHEMBL10091935 0.90 AKT2 (0.60) AKT2PDPK1NTRK1NTRK2MET
SCHEMBL10091933 0.88 AKT2 (0.52) AKT2PDPK1NTRK1NTRK2KDR
SCHEMBL396456 0.88 AKT2 (0.52) AKT2PDPK1NTRK1NTRK2KDR
SCHEMBL398703 0.84 KDR (0.53) AKT2NTRK1NTRK2KDRFLT3
SCHEMBL398702 0.84 KDR (0.53) AKT2NTRK1NTRK2KDRFLT3
SCHEMBL396921 0.84 NTRK2 (0.52) AKT2NTRK1NTRK2KDRFLT3
SCHEMBL10091939 0.84 NTRK2 (0.52) AKT2NTRK1NTRK2KDRFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 US claimed
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 US disclosed